243 related articles for article (PubMed ID: 35558160)
1. Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma.
Gartrell RD; Enzler T; Kim PS; Fullerton BT; Fazlollahi L; Chen AX; Minns HE; Perni S; Weisberg SP; Rizk EM; Wang S; Oh EJ; Guo XV; Chiuzan C; Manji GA; Bates SE; Chabot J; Schrope B; Kluger M; Emond J; Rabadán R; Farber D; Remotti HE; Horowitz DP; Saenger YM
Oncoimmunology; 2022; 11(1):2066767. PubMed ID: 35558160
[TBL] [Abstract][Full Text] [Related]
2. Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy.
Michelakos T; Cai L; Villani V; Sabbatino F; Kontos F; Fernández-Del Castillo C; Yamada T; Neyaz A; Taylor MS; Deshpande V; Kurokawa T; Ting DT; Qadan M; Weekes CD; Allen JN; Clark JW; Hong TS; Ryan DP; Wo JY; Warshaw AL; Lillemoe KD; Ferrone S; Ferrone CR
J Natl Cancer Inst; 2021 Feb; 113(2):182-191. PubMed ID: 32497200
[TBL] [Abstract][Full Text] [Related]
3. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer.
Pu N; Zhao G; Yin H; Li JA; Nuerxiati A; Wang D; Xu X; Kuang T; Jin D; Lou W; Wu W
J Transl Med; 2018 Oct; 16(1):294. PubMed ID: 30359281
[TBL] [Abstract][Full Text] [Related]
4. Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma.
Ene-Obong A; Clear AJ; Watt J; Wang J; Fatah R; Riches JC; Marshall JF; Chin-Aleong J; Chelala C; Gribben JG; Ramsay AG; Kocher HM
Gastroenterology; 2013 Nov; 145(5):1121-32. PubMed ID: 23891972
[TBL] [Abstract][Full Text] [Related]
5. Local and systemic immune profiles of human pancreatic ductal adenocarcinoma revealed by single-cell mass cytometry.
Brouwer TP; de Vries NL; Abdelaal T; Krog RT; Li Z; Ruano D; Fariña A; Lelieveldt BPF; Morreau H; Bonsing BA; Vahrmeijer AL; Koning F; de Miranda NFCC
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35793870
[TBL] [Abstract][Full Text] [Related]
6. Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3+ Cancer Cells in Locally Advanced Pancreatic Cancer.
Boucher Y; Posada JM; Subudhi S; Kumar AS; Rosario SR; Gu L; Kumra H; Mino-Kenudson M; Talele NP; Duda DG; Fukumura D; Wo JY; Clark JW; Ryan DP; Fernandez-Del Castillo C; Hong TS; Pittet MJ; Jain RK
Clin Cancer Res; 2023 Apr; 29(8):1605-1619. PubMed ID: 36749873
[TBL] [Abstract][Full Text] [Related]
7. The immunological impact of preoperative chemoradiotherapy on the tumor microenvironment of pancreatic cancer.
Okubo S; Suzuki T; Hioki M; Shimizu Y; Toyama H; Morinaga S; Gotohda N; Uesaka K; Ishii G; Takahashi S; Kojima M
Cancer Sci; 2021 Jul; 112(7):2895-2904. PubMed ID: 33931909
[TBL] [Abstract][Full Text] [Related]
8. Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome.
Liudahl SM; Betts CB; Sivagnanam S; Morales-Oyarvide V; da Silva A; Yuan C; Hwang S; Grossblatt-Wait A; Leis KR; Larson W; Lavoie MB; Robinson P; Dias Costa A; Väyrynen SA; Clancy TE; Rubinson DA; Link J; Keith D; Horton W; Tempero MA; Vonderheide RH; Jaffee EM; Sheppard B; Goecks J; Sears RC; Park BS; Mori M; Nowak JA; Wolpin BM; Coussens LM
Cancer Discov; 2021 Aug; 11(8):2014-2031. PubMed ID: 33727309
[TBL] [Abstract][Full Text] [Related]
9. Intraepithelial Attack Rather than Intratumorally Infiltration of CD8+T Lymphocytes is a Favorable Prognostic Indicator in Pancreatic Ductal Adenocarcinoma.
Zhang J; Wang YF; Wu B; Zhong ZX; Wang KX; Yang LQ; Wang YQ; Li YQ; Gao J; Li ZS
Curr Mol Med; 2017; 17(10):689-698. PubMed ID: 29521231
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemotherapy drives intratumoral T cells toward a proinflammatory profile in pancreatic cancer.
Heiduk M; Plesca I; Glück J; Müller L; Digomann D; Reiche C; von Renesse J; Decker R; Kahlert C; Sommer U; Aust DE; Schmitz M; Weitz J; Seifert L; Seifert AM
JCI Insight; 2022 Nov; 7(22):. PubMed ID: 36509285
[TBL] [Abstract][Full Text] [Related]
11. Infiltration of CD3+ and CD8+ lymphocytes in association with inflammation and survival in pancreatic cancer.
Tushoski-Alemán GW; Herremans KM; Underwood PW; Akki A; Riner AN; Trevino JG; Han S; Hughes SJ
PLoS One; 2024; 19(2):e0297325. PubMed ID: 38346068
[TBL] [Abstract][Full Text] [Related]
12. CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model.
Wang R; Chen J; Wang W; Zhao Z; Wang H; Liu S; Li F; Wan Y; Yin J; Wang R; Li Y; Zhang C; Zhang H; Cao Y
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086948
[TBL] [Abstract][Full Text] [Related]
13. The spatial coexistence of TIGIT/CD155 defines poorer survival and resistance to adjuvant chemotherapy in pancreatic ductal adenocarcinoma.
Ma H; Chen X; Mo S; Mao X; Chen J; Liu Y; Lu Z; Yu S; Chen J
Theranostics; 2023; 13(13):4601-4614. PubMed ID: 37649613
[No Abstract] [Full Text] [Related]
14. Accumulation of FOXP3+T-cells in the tumor microenvironment is associated with an epithelial-mesenchymal-transition-type tumor budding phenotype and is an independent prognostic factor in surgically resected pancreatic ductal adenocarcinoma.
Wartenberg M; Zlobec I; Perren A; Koelzer VH; Gloor B; Lugli A; Karamitopoulou E
Oncotarget; 2015 Feb; 6(6):4190-201. PubMed ID: 25669968
[TBL] [Abstract][Full Text] [Related]
15. Machine Learning Links T-cell Function and Spatial Localization to Neoadjuvant Immunotherapy and Clinical Outcome in Pancreatic Cancer.
Blise KE; Sivagnanam S; Betts CB; Betre K; Kirchberger N; Tate BJ; Furth EE; Dias Costa A; Nowak JA; Wolpin BM; Vonderheide RH; Goecks J; Coussens LM; Byrne KT
Cancer Immunol Res; 2024 May; 12(5):544-558. PubMed ID: 38381401
[TBL] [Abstract][Full Text] [Related]
16. Tumor-Infiltrating B- and T-Cell Repertoire in Pancreatic Cancer Associated With Host and Tumor Features.
Pineda S; López de Maturana E; Yu K; Ravoor A; Wood I; Malats N; Sirota M
Front Immunol; 2021; 12():730746. PubMed ID: 34630409
[TBL] [Abstract][Full Text] [Related]
17. DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma.
Fitzgerald AA; Wang S; Agarwal V; Marcisak EF; Zuo A; Jablonski SA; Loth M; Fertig EJ; MacDougall J; Zhukovsky E; Trivedi S; Bhatia D; O'Neill V; Weiner LM
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34737215
[TBL] [Abstract][Full Text] [Related]
18. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
[TBL] [Abstract][Full Text] [Related]
19. Comparative characterization of stroma cells and ductal epithelium in chronic pancreatitis and pancreatic ductal adenocarcinoma.
Helm O; Mennrich R; Petrick D; Goebel L; Freitag-Wolf S; Röder C; Kalthoff H; Röcken C; Sipos B; Kabelitz D; Schäfer H; Oberg HH; Wesch D; Sebens S
PLoS One; 2014; 9(5):e94357. PubMed ID: 24797069
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant Chemotherapy Is Associated with Altered Immune Cell Infiltration and an Anti-Tumorigenic Microenvironment in Resected Pancreatic Cancer.
Dias Costa A; Väyrynen SA; Chawla A; Zhang J; Väyrynen JP; Lau MC; Williams HL; Yuan C; Morales-Oyarvide V; Elganainy D; Singh H; Cleary JM; Perez K; Ng K; Freed-Pastor W; Mancias JD; Dougan SK; Wang J; Rubinson DA; Dunne RF; Kozak MM; Brais L; Reilly E; Clancy T; Linehan DC; Chang DT; Hezel AF; Koong AC; Aguirre AJ; Wolpin BM; Nowak JA
Clin Cancer Res; 2022 Dec; 28(23):5167-5179. PubMed ID: 36129461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]